The addition of immunotherapy to chemotherapy for malignant skin cancer that has spread does not improve survival rates, researchers have found, and patients have more serious side effects, such as anemia, when the two treatments are combined.
Researchers have made significant advances in the treatment of metastatic malignant melanoma - one of the most difficult cancers to treat successfully once it has started to spread - according to a study to be presented at Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin on Thursday.
Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.
Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.
The German Cancer Society has worked out new guidelines for the diagnosis and treatment of malignant melanoma - a disease with unfavorable prognosis.
A new, less toxic way to treat malignant melanoma (skin cancer) is being developed by medicinal chemists at Reading University. They have produced a range of prodrugs: compounds that offer the potential to be converted to toxic molecules only within the vicinity of tumours. These prodrugs aim to reduce the toxicity of treatment.
UK scientists have developed a 3D test for malignant melanoma that can identify problems not easily spotted in a standard two-dimensional view of the pattern on the skin. The researchers describe the technique in detail in the latest issue of the International Journal of Modelling, Identification and Control.
Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).